2 Information about ponesimod

Marketing authorisation indication

2.1 Ponesimod (Ponvory, Janssen) is indicated for 'the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features'.

Dosage in the marketing authorisation

2.2 The dosage schedule for ponesimod is available in the summary of product characteristics for ponesimod.


2.3 The list price for ponesimod is commercial in confidence so cannot be reported here. The company has a commercial arrangement. This makes ponesimod available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)